|
|
|
Stelazine advertisement, 1987. American Journal of Psychiatry, Vol. 144, No. 12. New Data on Low-Dose Triflluoperazine: Reduced Symptoms in 86% of Disturbed Elderly Patients Stelazine® brand of trifluoperazine HCl Tablets: 1, 2, 5 and 10 mg., Concentrate: 10 mg./ml. New Low-Dose Study ~ A six-week, double-blind study compared the safety and efficacy of trifluoperazine with haloperidol in the management of psychotic symptoms in disturbed elderly patients. Conclusions: * Comparable efficacy in reducing symptoms of psychoses associated with chronic brain syndromes and senile psychosis in elderly patients. * Comparable type and incidence of adverse reactions * No extrapyramidal symptoms (EPS) developed in patients on either drug Favorable Safety Profile ~ Sedation was the most commonly reported adverse reaction. No extrapyramidal symptoms (EPS) developed, and minimal abnormal involuntary movements present in four patients at baseline showed no increase in severity during the trial. Elderly patients should be observed closely since they appear to be more susceptible to hypertension and neuromuscular reactions. Be sure you're the doctor... always specify Stelazine Dispense as Written © SK&F Co., 1987 |